Design, Synthesis and Evaluation of Peroxisome Proliferator-Activated Receptor /&bgr;Dual Agonists for the Treatment of Type 2 Diabetes

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|4|1|27-32

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.4, Iss.1, 2007-01, pp. : 27-32

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

By Miller Anne R   Etgen Garret J  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 9, 2003-09 ,pp. : 1489-1500

Informa Healthcare

Access to resources Recommend Favorite

Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway

By  

Current Pharmacogenomics, Vol. 3, Iss. 2, 2005-06 ,pp. : 119-128

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor-γ Agonists for Management and Prevention of Vascular Disease in Patients with and without Diabetes Mellitus

By Ríos-Vázquez Ramón   Marzoa-Rivas Raquel   Gil-Ortega Ignacio   Juan Carlos Kaski  

American Journal of Cardiovascular Drugs, Vol. 6, Iss. 4, 2006-01 ,pp. : 231-242

Adis International

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR)&bgr; /&dgr;: A New Potential Therapeutic Target for the Treatment of Metabolic Syndrome

By  

Current Molecular Pharmacology, Vol. 2, Iss. 1, 2009-01 ,pp. : 46-55

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Updates on Peroxisome Proliferator-Activated Receptor δ Agonists for the Treatment of Metabolic Syndrome

By  

Medicinal Chemistry, Vol. 12, Iss. 1, 2016-02 ,pp. : 3-21

Bentham Science Publishers

Access to resources Recommend Favorite